Investing News NetworkYour trusted source for investing success

Videos
Companies
Press Releases
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Private Placements
Trending
Trending Articles

How Would a New BRICS Currency Affect the US Dollar? (Updated 2024)

Could the Silver Price Really Hit US$100 per Ounce? (Updated 2024)

Top 10 Copper-producing Companies (Updated 2024)

Investing in Graphene Companies

Top 10 Countries for Natural Gas Production (Updated 2024)

Can You Invest in Elon Musk’s Neuralink?

7 Biggest Lithium-mining Companies

Where Does Tesla Get its Lithium? (Updated 2024)

Rare Earths Reserves: Top 8 Countries (Updated 2024)

Trending Press Releases

CORRECTION - Brunswick Exploration Drills 93.45 Meters at 1.55% Li2O at MR-6

Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement

Cote d’Ivoire Acquisition Completes

$8 Million Capital Raise to Commence Bringing the Mt Boppy Gold Mine into Production in 2024

Spectacular Vein Gold Discovery Expands Christmas Gift Shear

Uranium Sector Expected to See a Run as Positive Momentum and Demand Builds

More Press Releases
Trending Companies

Firebird Metals

FRB:AU

Element79 Gold Corp.

ELEM:CC

Rua Gold

RUA:CNX

Elixir Energy

EXR:AU
More Companies
Trending Reports

2024 Lithium Market Outlook (Updated for Q2)

2024 Gold Outlook Report

Lithium Outlook for Australia

2024 Life Science Outlook Report

More Outlook Reports
Resource
Resource
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Tech
Tech
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Life Science
Life Science
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Gold
Copper
Uranium
Oil and Gas
Artificial Intelligence
Biotech
loader

Forte Biosciences Inc.

NASDAQ:FBRX
Press Releases

Forte Biosciences Inc is a clinical-stage biopharmaceutical company, focused on dermatology. The company is developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and pediatric patients with atopic dermatitis. It plans to advance FB-401 into a randomized Phase 2 clinical trial.

×